{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:24:53Z","timestamp":1794223493989,"version":"4.8.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. The immunosuppressive tumor microenvironment (TME) and limited response to immune checkpoint blockade (ICB) therapy remain major obstacles to improving HCC prognosis. Interleukin-33 (IL-33) is a multifunctional cytokine that plays critical roles in cancer development; however, its function in HCC remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Cell proliferation was evaluated using colony formation and 5-ethynyl-2\u2032-deoxyuridine (EdU) staining assays. Tumor-bearing models were established in both immunocompetent and immunodeficient mice. Multiplex immunofluorescence and flow cytometry were performed to assess TME characteristics. RNA sequencing and Western blot analyses were conducted to investigate the underlying mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We found that IL-33 downregulation was significantly associated with shorter survival in patients with HCC. IL-33 treatment markedly inhibited tumor progression, whereas endogenous IL-33 blockade accelerated tumor growth in immunocompetent mice. However, IL-33 showed no significant effect on cell proliferation\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      and failed to suppress tumor growth in immunodeficient mice lacking T cells. IL-33 administration notably reduced immunosuppressive tumor-associated macrophages and myeloid-derived suppressor cells, while substantially increasing CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, particularly functional interferon (IFN)-\u03b3\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, within the TME. Mechanistically, IL-33 activated the stimulator of interferon genes\/interferon regulatory factor signaling axis, enhanced IFN-\u03b3 secretion, and inhibited Rictor and programmed death 1 expression in mouse tumors. Furthermore, HCC specimens with high IL-33 expression exhibited more tertiary lymphoid structures. In addition, combined IL-33 and anti-programmed death ligand-1 therapy synergistically reduced tumor burden and further enhanced antitumor immunity\n                      <jats:italic toggle=\"yes\">in vivo<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These findings indicate that IL-33 alleviates immunosuppression and enhances ICB efficacy, providing novel insights into its role in HCC immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004205","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:00:06Z","timestamp":1790733606000},"page":"3295-3307","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Interleukin-33 alleviates the immunosuppressive tumor microenvironment and enhances anti-programmed death ligand-1 immunotherapy efficacy in hepatocellular carcinoma"],"prefix":"10.1097","volume":"139","author":[{"given":"Ensi","family":"Ma","sequence":"first","affiliation":[{"name":"Liver Transplantation Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yange","family":"Gu","sequence":"additional","affiliation":[{"name":"Institute of Organ Transplantation, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiao","family":"He","sequence":"additional","affiliation":[{"name":"Surgical Training Base, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunshu","family":"Ma","sequence":"additional","affiliation":[{"name":"Hepatobiliary Surgery Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengran","family":"Jiang","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China"},{"name":"Institute of Organ Transplantation, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanbao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China"},{"name":"Institute of Organ Transplantation, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Huashan Hospital, Fudan University, Shanghai 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Hepatobiliary Surgery Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China"},{"name":"Cancer Metastasis Institute, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Liver Transplantation Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China"},{"name":"Institute of Organ Transplantation, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"R1-20261109","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J Clinicians"},{"key":"R2-20261109","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/CM9.0000000000003828","article-title":"Burden of liver cancer and underlying etiologies in China from 1990 to 2021: A systematic analysis from the Global Burden of Disease Study 2021","volume":"139","author":"Li","year":"2026","journal-title":"Chin Med J"},{"key":"R3-20261109","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/liv.14817","article-title":"Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis","volume":"41","author":"Casadei-Gardini","year":"2021","journal-title":"Liver International"},{"key":"R4-20261109","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"R5-20261109","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"R6-20261109","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"R7-20261109","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic targeting of the tumor microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov"},{"key":"R8-20261109","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1038\/s41467-021-24010-1","article-title":"Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma","volume":"12","author":"Ho","year":"2021","journal-title":"Nat Commun"},{"key":"R9-20261109","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s43657-023-00136-8","article-title":"A noninvasive approach to evaluate tumor immune microenvironment and predict outcomes in hepatocellular carcinoma","volume":"3","author":"Wu","year":"2023","journal-title":"Phenomics"},{"key":"R10-20261109","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","article-title":"Tertiary lymphoid structures in the era of cancer immunotherapy","volume":"19","author":"Saut\u00e8s-Fridman","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"R11-20261109","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41419-025-08359-5","article-title":"CCL20 secreted by KRT15high tumor cells promotes tertiary lymphoid structure formation and enhances anti-PD-1 therapy response in HPV+HNSCC","volume":"17","author":"Zhang","year":"2025","journal-title":"Cell Death Dis"},{"key":"R12-20261109","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg3750","article-title":"Comprehensive analysis of spatial architecture in primary liver cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Sci Adv"},{"key":"R13-20261109","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"Propper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R14-20261109","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2014-10-606830","article-title":"The IL-33\/ST2 axis augments effector T-cell responses during acute GVHD","volume":"125","author":"Reichenbach","year":"2015","journal-title":"Blood"},{"key":"R15-20261109","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-immunol-101320-124243","article-title":"Emerging functions of IL-33 in homeostasis and immunity","volume":"40","author":"Dwyer","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"R16-20261109","article-title":"Interleukin-33 is a novel immunosuppressor that protects cancer cells from TIL killing by a macrophage-mediated shedding mechanism","volume":"8","author":"Wu","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"R17-20261109","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.7150\/thno.80483","article-title":"Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer","volume":"13","author":"Song","year":"2023","journal-title":"Theranostics"},{"key":"R18-20261109","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl7209","article-title":"Gasdermin D\u2013mediated release of IL-33 from senescent hepatic stellate cells promotes obesity-associated hepatocellular carcinoma","volume":"7","author":"Yamagishi","year":"2022","journal-title":"Sci Immunol"},{"key":"R19-20261109","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1186\/s12967-020-02661-w","article-title":"Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment","volume":"18","author":"Wang","year":"2020","journal-title":"J Transl Med"},{"key":"R20-20261109","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.4049\/jimmunol.1800627","article-title":"IL-33 released in the liver inhibits tumor growth via promotion of CD4+ and CD8+ T cell responses in hepatocellular carcinoma","volume":"201","author":"Jin","year":"2018","journal-title":"J Immunol"},{"key":"R21-20261109","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay1813","article-title":"Tumor-initiating cells establish an IL-33\u2013TGF-\u03b2 niche signaling loop to promote cancer progression","volume":"369","author":"Taniguchi","year":"2020","journal-title":"Science"},{"key":"R22-20261109","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/s41388-019-1078-x","article-title":"The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-\u03b1\/IL-33\/ST2L signaling promotes gastric cancer metastasis","volume":"39","author":"Zhou","year":"2020","journal-title":"Oncogene"},{"key":"R23-20261109","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41423-025-01365-9","article-title":"IL33-induced lipid droplet formation in mature low-density neutrophils drives colorectal cancer liver metastasis","volume":"22","author":"Zhang","year":"2025","journal-title":"Cell Mol Immunol"},{"key":"R24-20261109","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ccell.2025.02.017","article-title":"Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33","volume":"43","author":"Lamorte","year":"2025","journal-title":"Cancer Cell"},{"key":"R25-20261109","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/hep.27728","article-title":"Tumor-infiltrating, interleukin-33\u2013producing effector-memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival","volume":"61","author":"Brunner","year":"2015","journal-title":"Hepatology"},{"key":"R26-20261109","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41586-024-08426-5","article-title":"IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer","volume":"638","author":"Amisaki","year":"2025","journal-title":"Nature"},{"key":"R27-20261109","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abq3362","article-title":"SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape","volume":"16","author":"Wang","year":"2023","journal-title":"Sci Signal"},{"key":"R28-20261109","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"R29-20261109","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/0008-5472.CAN-05-1299","article-title":"Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host","volume":"66","author":"Huang","year":"2006","journal-title":"Cancer Res"},{"key":"R30-20261109","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-12-3381","article-title":"Higher frequencies of GARP+CTLA-4+Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality","volume":"73","author":"Kalathil","year":"2013","journal-title":"Cancer Res"},{"key":"R31-20261109","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/HEP.0000000000001433","article-title":"Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy","volume":"83","author":"Su","year":"2026","journal-title":"Hepatology"},{"key":"R32-20261109","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.immuni.2020.05.013","article-title":"Structures and mechanisms in the cGAS-STING innate immunity pathway","volume":"53","author":"Zhang","year":"2020","journal-title":"Immunity"},{"key":"R33-20261109","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41419-025-07964-8","article-title":"CAD hijacks STING to impair antitumor immunity and radiotherapy efficacy of colorectal cancer","volume":"16","author":"Cai","year":"2025","journal-title":"Cell Death Dis"},{"key":"R34-20261109","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hep.32335","article-title":"Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway","volume":"77","author":"Ma","year":"2023","journal-title":"Hepatology"},{"key":"R35-20261109","doi-asserted-by":"crossref","first-page":"7930","DOI":"10.1038\/s41467-024-52170-3","article-title":"Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS\/STING signaling","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"key":"R36-20261109","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1097\/CM9.0000000000003904","article-title":"The cGAS-STING signaling pathway as a therapeutic target in human diseases","volume":"138","author":"Xiao","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"R37-20261109","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1186\/s12967-023-04799-9","article-title":"Rictor mediates p53 deactivation to facilitate the malignant transformation of hepatocytes and promote hepatocarcinogenesis","volume":"21","author":"Wang","year":"2023","journal-title":"J Transl Med"},{"key":"R38-20261109","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41392-021-00801-2","article-title":"An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity","volume":"6","author":"Wei","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R39-20261109","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev-med-042220-021121","article-title":"Hepatocellular carcinoma immunotherapy","volume":"73","author":"Sperandio","year":"2022","journal-title":"Annu Rev Med"},{"key":"R40-20261109","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216038","article-title":"Immune checkpoint inhibitor resistance in hepatocellular carcinoma","volume":"555","author":"Wang","year":"2023","journal-title":"Cancer Lett"},{"key":"R41-20261109","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2214478","article-title":"Trial watch: Immunotherapeutic strategies on the horizon for hepatocellular carcinoma","volume":"12","author":"Koh","year":"2023","journal-title":"Oncoimmunology"},{"key":"R42-20261109","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41423-022-00848-3","article-title":"The combination of PD-1 blockade with interferon-\u03b1 has a synergistic effect on hepatocellular carcinoma","volume":"19","author":"Zhu","year":"2022","journal-title":"Cell Mol Immunol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:01:02Z","timestamp":1794222062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":42,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004205","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"assertion":[{"value":"2025-06-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}